Author Topic: (Abst.) Impact of trial design ... on identifying progressive MS therapies  (Read 46 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8588
  • MS diagnosed 1980
  • Location: Pacific Northwest
Although this abstract doesn't provide the specific information about clinical trials or treatments that are discussed in the article, it clearly states what many have long suspected: 

Since disability is multifaceted, progressive patients are heterogeneous, and the drivers of disease progression are still unclear, it has been difficult to identify the most informative outcome measures for progressive trials. Historically, secondary outcome measures have focused on inflammatory measures, which contributed to the recent identification of immunomodulatory therapies benefiting younger patients with more inflammatory progressive MS. Meanwhile, agents capable of treating late-stage disease have remained elusive.

From researchers at the University of Michigan, "Impact of trial design and patient heterogeneity  on the identification of clinically effective therapies for progressive MS," from Multiple Sclerosis Journal, October 10, 2018:
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post March 11, 2017, 07:08:23 am
by agate
0 Replies
Last post November 02, 2018, 07:30:04 am
by agate
0 Replies
Last post January 25, 2019, 02:31:15 pm
by agate
0 Replies
Last post June 08, 2020, 04:03:04 pm
by agate
0 Replies
Last post June 09, 2020, 09:28:18 pm
by agate